The earnings call presented a mix of positive developments in commercial growth, clinical trial results, and financial management, alongside operational challenges and high net loss. The positive aspects, including strong revenue growth and clinical trial outcomes, slightly outweigh the lowlights, indicating a cautiously optimistic outlook.

Company Guidance

During GRAIL's second quarter 2025 earnings call, the company highlighted several key performance metrics and financial results. GRAIL reported second-quarter revenue of $35.5 million, an 11% increase from the previous year, with screening revenue accounting for $34.4 million. The company sold over 45,000 Galleri tests in the quarter, contributing to a total of more than 370,000 tests prescribed by over 15,000 healthcare providers since the product's commercial launch in 2021. Galleri's positive predictive value (PPV) was notably higher in the PATHFINDER 2 study compared to the first PATHFINDER study, with a specificity of 99.5% and a cancer signal origin accuracy of 88%. Additionally, GRAIL's cash position was $606.1 million, and it revised its full-year cash burn guidance to no more than $310 million, a decrease of more than 40% compared to 2024. The company also plans to submit detailed PATHFINDER 2 study results for presentation at the ESMO Congress 2025 in October.

Strong Commercial Growth

Galleri test orders grew significantly with more than 45,000 commercial tests sold in Q2, contributing to over 370,000 tests prescribed since its launch in 2021.

Positive Clinical Trial Results

PATHFINDER 2 study showed substantially greater additional cancer detection and a higher positive predictive value compared to the first PATHFINDER study.

Revenue Growth

GRAIL reported Q2 revenue of $35.5 million, an 11% increase from the same period in 2024, with U.S. Galleri revenue up 21%.

Partnership Expansion

GRAIL established new partnerships, including with Rush University System for Health and Everlywell, to expand the availability of Galleri.

Improved Financials

Net loss improved by 93% compared to Q2 2024, with cash burn guidance updated to no more than $310 million for 2025, down from previously projected numbers.

GRAIL Inc (GRAL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GRAL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-3.41 / -	-3.94	―	―	―
Aug 12, 2025	2025 (Q2)	-3.57 / -3.18	-51.055	93.77% (+47.88)	―
May 13, 2025	2025 (Q1)	-3.99 / -3.10	-7.05	56.03% (+3.95)	―
Feb 20, 2025	2024 (Q4)	-4.97 / -2.89	-6.039	52.14% (+3.15)	―
Nov 12, 2024	2024 (Q3)	-6.43 / -3.94	-28.711	86.28% (+24.77)	―
Aug 13, 2024	2024 (Q2)	- / -51.05	-6.217	-721.22% (-44.84)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GRAL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$33.60	$33.98	+1.13%
May 13, 2025	$42.89	$32.89	-23.32%
Feb 20, 2025	$47.76	$40.73	-14.72%
Nov 12, 2024	$15.09	$15.92	+5.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does GRAIL Inc (GRAL) report earnings?

GRAIL Inc (GRAL) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is GRAIL Inc (GRAL) earnings time?

GRAIL Inc (GRAL) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GRAL EPS forecast?

GRAL EPS forecast for the fiscal quarter 2025 (Q3) is -3.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing